Abstract:Background: Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied. Methods: An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells' ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo. Results: By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice. Conclusions: CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment.

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

ECRG4 Acts As a Tumor Suppressor Gene Frequently Hypermethylated in Human Breast Cancer.

Targeting Crmp-4 by Lentivirus-Mediated Rna Interference Inhibits Sw480 Cell Proliferation and Colorectal Cancer Growth

Suppressed Mir-424 Expression Via Upregulation of Target Gene Chk1 Contributes to the Progression of Cervical Cancer

Upregulation of CRMP4, a New Prostate Cancer Metastasis Suppressor Gene, Inhibits Tumor Growth in a Nude Mouse Intratibial Injection Model.

CMTM4 is Frequently Downregulated and Functions As a Tumour Suppressor in Clear Cell Renal Cell Carcinoma

CMTM4 Inhibits Cell Proliferation and Migration Via AKT, ERK1/2, and STAT3 Pathway in Colorectal Cancer

Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer

Collapsin Response Mediator Protein 4 Isoforms (crmp4a and CRMP4b) Have Opposite Effects on Cell Proliferation, Migration, and Invasion in Gastric Cancer.

EZH2-mediated Epigenetic Activation of the CCL22/CCR4 Causing EMT Process Remodeling in Cervical Carcinoma

Unraveling the mechanisms of RECQL4-mediated cervical cancer progression through the PI3K/AKT pathway

Golgi Phosphoprotein 3 Promotes Cervical Cancer Progression via Wnt/β-catenin Mediated Epithelial-Mesenchymal Transition

Activation of the CCL22/CCR4 Causing EMT Process Remodeling under EZH2-mediated Epigenetic Regulation in Cervical Carcinoma.

The overexpression of MCPH1 inhibits cell growth through regulating cell cycle-related proteins and activating cytochrome c-caspase 3 signaling in cervical cancer

The Effects of Micro-429 on Inhibition of Cervical Cancer Cells Through Targeting ZEB1 and CRKL

MiR-34b Regulates Cervical Cancer Cell Proliferation and Apoptosis.

CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK

CRP‑1 Promotes the Malignant Behavior of Hepatocellular Carcinoma Cells Via Activating Epithelial‑mesenchymal Transition and Wnt/β‑catenin Signaling.

Cellular Retinoic Acid Binding Protein 2 (CRABP2), Up-regulated by HPV E6/E7, Leads to Aberrant Activation of the Integrin β1/FAK/ERK Signaling Pathway and Aggravates the Malignant Phenotypes of Cervical Cancer

MB-04 * EXPRESSION OF CRMP1 INHIBITS CELL PROLIFERATION OF MEDULLOBLASTOMA AND IS REGULATED BY HMGA1

MCPIP1 Elicits a Therapeutic Effect on Cervical Cancer by Facilitating XIAP mRNA Decay via Its Endoribonuclease Activity